Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pulmonary Fibrosis Foundation’s latest registry offers research opportunities

By Brian Buntz | August 24, 2022

Pulmonary Fibrosis FoundationThe Pulmonary Fibrosis Foundation (PFF) has launched the PFF Community Registry to facilitate research on pulmonary fibrosis (PF) and interstitial lung disease (ILD).

The PFF Community Registry collects self-reported data from patients, nonprofessional caregivers and biological family members via a secure online portal. Participation is voluntary.

“There’s a research opportunity to see if there are any differences in how patients perceive their diagnosis and care relative to how physicians input that data within the medical chart,” PFF Registry VP Junelle Speller said.

The Pulmonary Fibrosis Foundation is enrolling individuals in the Community Registry, including lung transplant recipients and patients diagnosed with pulmonary fibrosis or interstitial lung disease, Speller said.

The organization plans on conducting follow-up surveys at six-month intervals. “We will check in on them, ask them if anything has changed, including new medications, new treatments or if they’ve had any hospitalizations,” Speller said.

The organization will contact select individuals regarding options for optional sub-studies.

Researchers interested in examining a specific cohort of patients with PFF, such as military vets, can develop a survey in conjunction with the PFF Registry team and delve into gathering such information.

The new registry will complement the organization’s existing patient registry, known as the PFF Patient Registry, which was established in 2016. “It is currently run across 42 PFF Care Centers within the U.S.,” Speller said. “We’ve grown to 74 Care Centers most recently.”

The registry currently includes data from more than 2,000 PF patients.

The PFF Patient Registry collects anonymized data from PF patients that researchers can use to understand what causes the condition, improve diagnosis and care and pave the way for new treatments and a potential cure.

The registry contains data related to medications, medical outcomes and events, demographic data and other health conditions. “Between 2016 and 2018, patients were given an opportunity to consent to give a one-time blood sample,” Speller said. “Those blood samples have been wonderful in terms of research.”

“We have medical data, biosample data, and then high-resolution computed tomography (HRCT) images,” Speller said. The registry also includes patient-reported outcomes. “Patients have an opportunity to report on their quality of life every six months..”

The PFF has multiple research efforts, including the PRECISIONS study, which is investigating whether N-Acetyl-cysteine (NAC) is effective for some idiopathic pulmonary fibrosis patients with a specific genetic variant.

The organization has also established the Prognostic Lung Fibrosis Consortium (PROLIFIC), which brings together a variety of pharmaceutical companies united in bolstering drug development in pulmonary fibrosis.

Ultimately, the PFF’s focus on registries can help gather data to answer many questions about PF and ILD. “There are about 250,000 individuals affected by PF or ILD, with about 50,000 newly diagnosed each year,” Speller said.


Filed Under: Pulmonology
Tagged With: Pulmonary Fibrosis Foundation
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Alex Zhavoronkov
Q&A: How Insilico Medicine’s AI identified a new IPF drug target in record time
Human Circulatory System Heart Anatomy
Fixed-dose macitentan-tadalafil polypill outperforms monotherapies in PAH
Insilico's AI-powered robotics lab
CEO: Insilico on how AI can ‘imagine the perfect molecules’ for drug targets
Insilico Medicine
Insilico’s AI-discovered INS018_055 graduates to phase 2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE